Abstract: Disclosed herein are solid formulations of (R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide (Compound A) or a pharmaceutically acceptable salt thereof for preparing liquid suspensions. In another aspect, the instant application provides methods of preparation of liquid suspensions and kits of solid formulations comprising Compound A. In another aspect, the instant application provides methods of treating cancer with formulations of Compound A. Additionally, the instant disclosure provides methods of treating pediatric cancer patients by the administration of formulations of Compound A.

Abstract: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility, for example celecoxib, in an immediate-release fraction and a controlled-release, slow-release, programmed-release, timed-release, pulse-release, sustained-release or extended-release fraction. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders.